GCC2005

Phase 1Small molecule

GGC Cell Corporation

GCC2005 is one of 3 small molecule programs targeting Lymphoma, T-Cell. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoma, T-CellRecruiting

Lymphoma, T-CellPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Lymphoma, T-Cell

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 1

1 2

Cytoxan

BBaxter Healthcare Corporation

Phase 1

1 3

GCC2005

GGC Cell Corporation

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Lymphoma, T-Cell

NCT06699771

Clinical

Trials by Indication[1]

Lymphoma, T-Cell1 trial

A Phase 1, Multicenter Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of GCC2005 With Lymphodepleting Chemotherapy in Treatment of Patients With Relapsed or Refractory NK and T-cell Malignancies

Recruiting·GGC Cell Corporation·Phase 1·NCT06699771·53 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GCC2005. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GCC2005 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GCC2005. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GC Cell Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GGC Cell Corporation

GCC2005

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Lymphoma, T-Cell1 trial

References

Drug Info

Quick Facts

Related News